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Abstract
Background: Neurogenic inflammation is orchestrated by a large number of neuropeptides. Tachykinins
(substance P, neurokinin A and neurokinin B) are pro-inflammatory neuropeptides that may play an important role
in some autoimmune neuroinflammatory diseases. Autoimmunity may have a role in the pathogenesis of autism in
some patients. We are the first to measure serum neurokinin A levels in autistic children. The relationship between
serum levels of neurokinin A and anti-ribosomal P protein antibodies was also studied.
Methods: Serum neurokinin A and anti-ribosomal P protein antibodies were measured in 70 autistic children in
comparison to 48 healthy-matched children.
Results: Autistic children had significantly higher serum neurokinin A levels than healthy controls (P < 0.001).
Children with severe autism had significantly higher serum neurokinin A levels than patients with mild to
moderate autism (P < 0.001). Increased serum levels of neurokinin A and anti-ribosomal P protein antibodies were
found in 57.1% and 44.3%, respectively of autistic children. There was significant positive correlations between
serum levels of neurokinin A and anti-ribosomal P protein antibodies (P = 0.004).
Conclusions: Serum neurokinin A levels were elevated in some autistic children and they were significantly
correlated to the severity of autism and to serum levels of anti-ribosomal P protein antibodies. However, this is an
initial report that warrants further research to determine the pathogenic role of neurokinin A and its possible link
to autoimmunity in autism. The therapeutic role of tachykinin receptor antagonists, a potential new class of anti-
inflammatory medications, should also be studied in autism.
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Background
Neurogenic inflammation encompasses a series of vascu-
lar and non-vascular inflammatory responses, triggered
by the activation of primary sensory neurons, with a
subsequent release of inflammatory neuromediators.
This results in a neurally mediated immune inflamma-
tion [1,2]. Neuromediators are mainly released from
neurons. Immune and/or structural cells are secondary
sources of these mediators during immune inflammation
[3,4]. Neuromediators include neurotrophins and neuro-
peptides [4].
Neurogenic inflammation is orchestrated by a large
number of neuropeptides mainly including tachykinins.
Tachykinins (substance P, neurokinin A and neurokinin
B) have been considered as a group of neuropeptides
which are released from the excitatory part of the nona-
drenergic, noncholinergic excitatory nervous system
nerves after exposure to allergens. The biological activity
of tachykinins depends on their interaction with three
specific tachykinin receptors, neurokinin (NK)1 (specific
for substance P), NK2 (specific for neurokinin A) and
NK3 (specific for neurokinin B) receptors [5-7]. Tachy-
kinin receptor antagonists are a potential new class of
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eases [8-10].
Autoimmunity may have a role in the pathogenesis of
autism in a subgroup of patients. This may be indicated
b yt h ep r e s e n c eo fb r a i n - s p e c i f i ca u t o - a n t i b o d i e si n
some autistic children [11-17]. There is also an increase
in the frequency of autoimmune disorders among autis-
tic families [18-23]. Inspite of the fact that the origins of
autoimmunity in autism are unknown, the major histo-
compatibility complex genes and their products might
be involved [21,24,25].
Anti-ribosomal P protein antibodies are one group of
potentially pathogenic autoantibodies that has a specifi-
city for the functional center of the ribosomal P proteins
which is a family of highly conserved acidic phospho-
proteins primarily located on the stalk of the large (60
s) ribosomal subunit [26]. They bind 3 ribosomal pro-
teins identified as P0, P1 and P2 (38, 19 and 17-kDa,
respectively) by recognizing a certain epitope found in
those 3 proteins. Several possible pathogenic mechan-
isms for these antibodies in some autoimmune diseases
include their binding to epitopes on the cell membrane
surface, intracellular penetration, inhibition of protein
synthesis, production of pro-inflammatory cytokines and
cell apoptosis [27].
Evidence for an interaction between chronic inflam-
mation in autoimmune diseases and neural dysfunction
points to an involvement linking the nervous and the
immune system. In this context, neuropeptides, includ-
ing tackykinins and neurotrophins have been recognized
as key mediators of neuro-immune interactions in some
autoimmune diseases [28]. Thus, investigations regard-
ing the development of pharmacological compounds
specifically targeting these molecules could be of interest
[29].
This study was the first to measure serum neurokinin
A levels in a group of autistic children. The relationship
between serum levels of neurokinin A and anti-riboso-
mal P protein antibodies was also studied.
Methods
Study population
This cross-sectional study was conducted on 70 children
who had autism. They were recruited from the Autism
Research and Treatment Center, Faculty of Medicine,
King Saud University, Riyadh, Saudi Arabia. Patients
were fulfilling the criteria of the diagnosis of autism
according to the 4
th edition of the Diagnostic and Statis-
tical Manual of Mental Disorders [30]. The autistic
group comprised 55 males and 15 females. Their ages
ranged between 4 and 12 years (mean ± SD = 8.10 ±
2.52 years).
Exclusions criteria:
1- Patients who had associated neurological diseases
(such as cerebral palsy and tuberous sclerosis) and
metabolic disorders (eg. Phenylketonuria) were excluded
form the study.
2- Patients with associated allergic, inflammatory or
autoimmune disorders.
3- Patients who were receiving any medications.
The control group comprised 48 age- and sex-
matched apparently healthy children (37 males and 11
females). They were the healthy older siblings of the
healthy infants who attend the Well Baby Clinic, King
Khalid University Hospital, Faculty of Medicine, King
Saud University, Riyadh, Saudi Arabia for routine fol-
lowing up of their growth parameters. The control chil-
dren were not related to the children with autism, and
demonstrated no clinical findings suggestive of immuno-
logical or neuropsychiatric disorders. Their ages ranged
between 6 and 11 years (mean ± SD = 8.79 ± 2.89
years).
The local Ethical Committee of the Faculty of Medi-
cine, King Saud University, Riyadh, Saudi Arabia,
approved this study. In addition, an informed written
consent of participation in the study was signed by the
parents or the legal guardians of the studied subjects.
Study measurements
Clinical evaluation of autistic patients
This was based on clinical history taking from care-
givers, clinical examination and neuropsychiatric assess-
ment. In addition, the degree of the disease severity was
assessed by using the Childhood Autism Rating Scale
( C A R S )[ 3 1 ]w h i c hr a t e st h ec h i l do nas c a l ef r o mo n e
to four in each of fifteen areas (relating to people; emo-
tional response; imitation; body use; object use; listening
response; fear or nervousness; verbal communication;
non-verbal communication; activity level; level and con-
sistency of intellectual response; adaptation to change;
visual response; taste, smell and touch response and
general impressions). According to the scale, children
who have scored 30-36 have mild to moderate autism (n
= 34), while those with scores ranging between 37 and
60 points have a severe degree of autism (n = 36).
Serum assessment of neurokinin A
Serum levels of neurokinin A were evaluated with an
e n z y m e - l i n k e di m m u n o s o r b e n ta s s a y( E L I S A )k i tw h i c h
is highly sensitivie to neurokinin A. Neurokinin A like
immunoreactivity was measured using an antibody that
has originally been isolated from porcine spinal cord. It
shows 100% cross reactivity to neurokinin A with little
reactivity to other tachykinins (Peninsula laboratories,
611 Talorwat, Belmont, CA, USA). To increase accuracy,
all samples were analysed twice in two independent
experiments to assess the interassay variations and to
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No significant cross-reactivity or interference was
observed.
Measurement of serum anti-ribosomal P protein antibodies
Serum total IgG and IgM anti-ribosomal P protein anti-
bodies were measured by ELISA using ribosomal P pep-
tide-bovine serum albumin conjugate as an antigen
(Nunc immuno module F8 maxisorp; Nunc. Roskilde,
Denmark). To increase accuracy, all samples were ana-
lysed twice in two independent experiments to assess
the interassay variations and to ensure reproducibility of
the observed results (P > 0.05). No significant cross-
reactivity or interference was observed.
Statistical analysis
The results were analyzed by commercially available
software package (Statview, Abacus concepts, inc., Berk-
ley, CA, USA). The data were non-parametric, thus they
were presented as median and interquartile range (IQR),
which are between the 25
th and 75
th percentiles. Mann-
Whitney test was used for comparison between these
data. Chi-square test was used for comparison between
qualitative variables of the studied groups. Spearman’s
rho correlation coefficient “r” was used to determine the
relationship between different variables. For all tests, a
probability (P) of less than 0.05 was considered signifi-
cant. Patients were considered to have elevated serum
neurokinin A or anti-ribosomal P protein antibodies if
their levels were above the highest cut-off values (107.4
pg/ml and 92 units/ml, respectively) which were the
95
th percentiles of serum neurokinin A and anti-riboso-
mal P levels, respectively of healthy controls as the dis-
tribution of the data was non-parametric.
Results
Serum Neurokin A levels in autistic children and their
relation to the degree of the severity of autism
Autistic children had significantly higher serum neuroki-
nin A levels than healthy controls, P < 0.001 (table 1).
Increased serum neurokinin A levels were found in
57.1% (40/70) of autistic patients.
Patients with severe autism had significantly higher
serum neurokinin A levels than children with mild to
moderate autism, P < 0.001 (table 1). Also, the fre-
quency of increased serum neurokinin A levels was
significantly higher in children with severe autism (31/
36: 77.5%) than patients with mild to moderate autism
(9/34: 26.5%), P < 0.001. Moreover, there were signifi-
cant positive correlations between serum levels of neu-
rokinin A and CARS in autistic patients, P < 0.001
(Figure 1).
Male and female autistic children had comparable
values of serum neurokinin A (P = 0.52). In addition,
serum neurokinin A levels had no significant correla-
tions with the age of the children with autism (P =
0.68).
The relationship between the elevated serum levels of
neurokinin A and anti-ribosomal P protein antibodies in
autistic children
Increased serum levels of anti-ribosomal P protein anti-
bodies were found in 44.3% (31/70) of autistic patients.
Patients with elevated serum neurokinin A levels had
significantly higher serum levels of anti-ribosomal P
protein antibodies [median (IQR): 115 (467) U/ml) than
patients with normal serum neurokinin A levels [median
(IQR): 23.5 (248) U/ml), P = 0.02. In addition, there
were significant positive correlations between serum
levels of neurokinin A and anti-ribosomal P protein
antibodies in autistic patients, P = 0.004 (Figure 2).
Discussion
Tachykinins are traditionally viewed as neuropeptides
with well-defined functions as neurotransmitters. Tachy-
kinin peptides have also an impact on the function of
the immune system [32].
In our series, autistic children had significantly higher
serum neurokinin A levels than healthy controls, P <
0.001. Increased serum neurokinin A levels were found
in 57.1% of autistic patients. We could not trace data in
the literature concerning neurokinin A levels in the
blood of autistic patients to compare our results. This
study was the first to investigate serum neurokinin A
levels in autistic children.
In a recent study some neuropeptides were investi-
gated in autistic children. It reported increased serum
levels of neurotensin, while the other studied neuropep-
tides (b-endorphin and substance P) were not reported
to be increased in these children [33]. Many studies
reported that tachykinins may also be produced by non-





Healthy children (n = 48) 52.5 (31) 3.5
Patients with autism (n = 70) 130 (328) (< 0.001)
Patients with mild to moderate autism (n = 34) 54.5 (78) 5
Patients with severe autism (n = 36) 329 (649) (< 0.001)
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inflammatory stimuli and they exert profound influence
on the inflammatory responses by affecting multiple
aspects of immune cell function [32]. In one study, the
elevated sputum neurokinin A levels had significant
positive correlations to eosinophil counts in both blood
and sputum of asthmatic children during exacerbation
[34]. Thus, the reason behind the increase of serum
neurokinin A levels in autistic children may be the sti-
mulation of the immune cells, after exposure to some
environmental antigens (such as food allergens, infec-
tious agents and heavy metals), with a subequent
increase in the release of this tachykinin from these
cells.
Neuroendocrine hormones, including tackykinins, trig-
gered during stress may lead to immune dysregulation
resulting from altered cytokine production, resulting in
autoimmune or atopic diseases. Thus, the stress
response with subsequent induction of a dysregulation
of cytokine balance can trigger the hypothalamic-pitui-
tary-adrenal axis and sympathetic nervous system
through overproduction of neuropeptides and cytokines.
In several autoimmune diseases such as rheumatoid
arthritis, systemic lupus erythematosus (SLE), and dia-
betes mellitus, the immune dysregulation may be attri-
butable to the neuroendocrine-immune network
imbalance through overproduction of neuropeptides and
cytokines [35]. One member of tachykinins, substance P,
was reported to be increased in the cerebrospinal fluid
obtained from patients with multiple sclerosis. Similar
to autism, multiple sclerosis is an inflammatory disease
of the CNS that is generally believed to represent an
auto-immunological response to a component of myelin
triggered by an environmental factor, in a genetically
susceptible individual [36]. Substance P, through NK-1
receptors, contributes to the maintenance of CNS
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r = 0.62, p<0.001
Figure 1 Positive correlations between serum levels of neurokinin A and CARS in children with autism. CARS: Childhood Autism Rating
Scale.
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with the conventional anti-inflammatory treatments,
may enhance the success of the treatment of some auto-
immune diseases such as multiple sclerosis [37].
Tachykinin 1 gene is located in the candidate region
for autism and produces substance P and neurokinins.
These products modulate glutamatergic excitatory
synaptic transmission and are also involved in inflamma-
tion which could be involved in the autistic brain.
Therefore, tachykinin 1 gene may have some functions
associated with the presumable pathophysiology of aut-
ism. To elucidate the genetic background of autism, one
study analyzed the relationship between three single
nucleotide polymorphisms of the tachykinin 1 gene and
autism in the Japanese population, but no significant dif-
ference was observed between autistic children and
healthy controls [38].
In the present work, patients with severe autism had
significantly higher serum neurokinin A levels than
children with mild to moderate autism, P < 0.001. Also,
the frequency of increased serum neurokinin A levels
was significantly higher in children with severe autism
(77.5%) than patients with mild to moderate autism
(26.5%), P < 0.001. Moreover, there were significant
positive correlations between serum levels of neurokinin
A and CARS in autistic patients, P < 0.001. This may
indicate that the extent of the elevation of serum neuro-
kinin A was closely linked to the degree of the severity
of autism. However, it is not easy to determine whether
the increase in serum neurokinin A levels is a mere con-
sequence of autism or has a pathogenic role in the
disease.
While glial cells are recognized for their roles in main-
taining neuronal function, there is a growing evidence of
the ability of resident glial cells to initiate and/or aug-
ment inflammation following exposure to allergens,
trauma or infection in CNS. The tachykinins are found
throughout the CNS, with an evidence for both
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r = 0.34. p = 0.004
Figure 2 Positive correlations between serum levels of neurokinin A and anti-ribosomal P protein antibodies in children with autism.
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kinins are well known to augment inflammatory
responses at peripheral sites, such as the gastrointestinal
tract and skin, which raises the possibility that they
might serve a similar function within the brain. Tachyki-
nins may have a role in augmenting the immune func-
tions of CNS glial cells resulting in the progression of
damaging inflammation within the CNS [39]. Brain mast
cells in some autoimmune neuroinflammatory diseases
of CNS such as multiple sclerosis are activated by neural
factors, including tachykinins. Mast cells can stimulate
the activated T cells coming in contact with them at the
blood-brain barrier In addition, brain mast cells secrete
numerous proinflammatory and vasoactive molecules
that can disrupt the blood-brain barrier, a finding that
precedes clinical or pathologic signs of some autoim-
mune neuroinflammatory diseases of CNS [40].
Autoimmunity to CNS may have a pathogenic role in
autism [41-44]. This may be indicated by the presence
of brain-specific auto-antibodies in some autistic chil-
dren [11-17]. In our series, increased serum levels of
anti-ribosomal P protein antibodies were found in 44.3%
of autistic patients. This study was the first to investi-
gate serum levels of anti-ribosomal P protein antibodies
in autistic children. Auto antibodies are the hallmark of
autoimmune diseases. The reason behind the formation
of some auto-antibodies in some patients with autism is
not fully understood. It is speculated that autoimmune
reaction might be trigged by cross-reacting antigens in
t h ee n v i r o n m e n tr e s u l t i n gi nt h er e l e a s eo fs o m es e l f
antigens. These antigens may result in the induction of
autoimmune reactions through the activation of inflam-
matory cells in genetically susceptible individuals
[41,42].
Anti-ribosomal P protein antibodies are highly specific
for SLE, especially for the neuropsychiatric manifesta-
tions including psychosis, mood disorders, anxiety, cog-
nitive dysfunction and delirium [45]. A recent study has
demonstrated a strong association between the seroposi-
tivity of anti-ribosomal P protein antibodies and the pre-
sence of neuropsychiatric manifestations in a group of
children with SLE [46]. Ther ea r es o m es t u d i e si nt h e
literature relating anti-ribosomal P protein antibodies to
the pathogenesis of organ damage in SLE. The main
pathways described are cross-reaction with anti-dsDNA
antibodies, a cytotoxic effect on mesangium cell prolif-
eration, invasion into living cells and starting apoptosis,
a defect in the synthesis of apolipoprotein B resulting in
accumulation of lipids inside the cell, and downregula-
tion of the total protein synthesis. P proteins are post-
translationally modified (dephosphorylated) during
apoptosis, and a dysregulation in the normal clearance
of apoptotic cells leads to aberrant exposure of the
immune system to modified non self-antigens. This
could be one of the triggering events for the develop-
ment of anti-P autoimmune response in some autoim-
mune diseases [45].
Moreover, in an experimental study, mice that had
been received intra-cerebroventricular injection of anti-
ribosomal P protein antibodies developed depression-
like behaviors, which seems to be mediated by specific
binding of these antibodies to limbic system brain areas,
such as hippocampus and cingulate. It has been propsed
that anti-ribosomal P protein antibodies both directly or
indirectly affect CNS and produce a cytotoxic effect on
neuronal cells. The mechanism by which these antibo-
dies cross the blood brain barrier is unknown [47].
The potential role of neuropeptides in the progression
and amplification of the immune neurogenic inflamma-
tion is of a great interest. These effects are described by
the term immunological plasticity that include enhance-
ment of survival, differentiation, and/or proliferation of
immune cells and activation of the release of cytokines
or mediators [48]. Therefore, neurogenic inflammation
describes a vicious cycle of neuroimmune interactions
that amplify immunogenic inflammation and neuropep-
tides are cross talks between the immune and nervous
systems in immunogenic inflammation [49,50].
As neuropeptides were reported to have a possible
role in some systemic autoimmune diseases and autoim-
mune neuroinflammatory diseases [35-37], we have tried
to find a possible link between the elevated serum levels
of neurokinin A and anti-ribosomal P protein antibodies
in autism. In this work, patients with elevated serum
neurokinin A levels had significantly higher serum levels
of anti-ribosomal P protein antibodies than patients
with normal serum neurokinin A levels, P = 0.02. In
addition, there were significant positive correlations
between serum levels of neurokinin A and anti-riboso-
mal P protein antibodies in autistic patients, P = 0.004.
We could not trace data in the literature concerning the
relationship between serum levels of neurokinin A and
auto-antibodies in autistic patients to compare our
results. We are the first to study such a relationship.
The results of this study may indicate that the elevated
serum levels of neurokinin A may be a possible contri-
buting factor to the increased frequency of anti-riboso-
mal P protein antibodies in some autistic children.
However, this is an initial report that warrants further
research to determine the possible link between the ele-
vated serum levels of neurokinin A and anti-ribosomal
P protein antibodies.
After exposure to allergens, inflammatory cell (e.g.
eosinophils) derived tachykinins are a major second
source of these proinflammatory mediators [3,4] which
can alter the function of the immune system [32].
Tachykinins may induce the so called neurogenic
inflammation by recruitment and activation of the
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have modulatory effects on immune cells, in vivo, espe-
cially on T-helper (Th)1/Th2 balance. In addition, neu-
ropeptides can directly stimulate lymphocytes to
produce Th2 cytokines, going in line with the Th2 type
shifted immune response [51-53]. Th2 cells orchestrate
many aspects of pathologic immune responses including
effector functions of B-cells, mast cells and eosinophils.
These cells produce an array of cytokines such as IL4,
IL-5, IL-9 and IL-13. In some autistic children there is
an imbalance of T-helper (Th)1/Th2 subsets toward
Th2, which are responsible for allergic response and
production of antibodies [41].
Thus, the increased seum levels of neurokinin A may
explain the increased frequency of anti-ribosomal P pro-
tein antibodies in some autistic children as a result of
Th2 type shifted immune response. However, these data
should be treated with a great caution, until further
investigations are performed, as the seropositivity for
anti-ribosomal P protein antibodies in some autistic
children may be a mere association with the increased
serum levels of neurokinin A in autism. A more detailed
understanding of the interactions between tachykinins
and immune cells may provide the basis for the develop-
ment of new therapies for inflammatory and immune-
mediated diseases [32]. Recent findings point to tachyki-
nergic systems as promising targets of novel clinical
agents in many inflammatory diseases [7]. These agents
may antagonize NK2 receptors only [8] or may be NK1/
2 receptor antagonists [9,10]
Conclusions
Serum neurokinin A levels were elevated in some autis-
tic children and they were significantly correlated to the
severity of autism and to serum levels of anti-ribosomal
P protein antibodies. However, this is an initial report
that warrants further research to determine the patho-
genic role of neurokinin A and its possible link to auto-
immunity in autism. The therapeutic role of tachykinin
receptor antagonists, a potential new class of anti-
inflammatory medications, should also be studied in
autism.
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